medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (1)


Serum lipids and chronic hepatitis C genotype 4: interaction and significance

Khattab MA, Eslam M, Aly MM, Shatat M, Mousa YI, Abd-Aalhalim H, Aly H, Shaker Y

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 37-46
Archivo PDF: 112.27 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Hepatitis C. Fact Sheet Number 164, Revised October 2000. Available from: http:// www.who.int/mediacentre/factssheets/fs164len [Accessed 13 October 2010].

  2. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, et al . Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. J Hepatol 2011; 54: 1250-62.

  3. Ishizaka Y, Ishizaka N, Takahashi E, Unuma T, Tooda E, Hashimoto H, Nagai R, et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003; 67: 26-30.

  4. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60: 1139-51.

  5. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102; 2561-6.

  6. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of antihepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007; 105: 145-50.

  7. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, e t al. Lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-97.

  8. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.

  9. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103: 1383-9.

  10. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, et al. Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patient infected with hepatitis C. Hepatology 2003; 38: 75-85.

  11. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-81.

  12. Khattab MA, Abdel-Fattah ME, Eslam M, Abdelaleem A, Abdelaleem RA, Shatat M, Ali A, et al. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. J Clin Gastroenterol 2010; 44: 707-12.

  13. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.

  14. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.

  15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(Suppl. 1): s5-s10.

  16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.

  17. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-74.

  18. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29(Suppl. 2): 26-37.

  19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Exec. Summary of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

  20. Aslam F, Alam M, Lakkis NM. Hepatitis C and carotid atherosclerosis: a retrospective analysis. Atherosclerosis 2010; 209(2): 340-3.

  21. Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13: 56-61.

  22. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ. Serum lipids and their associations with viral levels and liver disease severity in a treatment- naïve chronic hepatitis C type 1-infected cohort. J Viral Hepat 2011; 18: e144-e152.

  23. Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003; 98: 1150-4.

  24. Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Chaturvedi N, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56: 1105-10.

  25. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of betalipoproteins and immunoglobulins. Med Microbiol Immunol 1993; 182: 329-34.

  26. Thomssen R, Bonk S, Propfe C, Heermann KH, Köchel HG, Uy A. Association of hepatitis C virus in human sera with B-lipoprotein. Med Microbiol Immunol 1992; 181: 293-300.

  27. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral- related steatosis. FASEB J 2002; 16: 185e94.

  28. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.

  29. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-7.

  30. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994; 5: 207-15.

  31. Sherlock S, James D. Diseases of the Liver and Biliary System. 10th Ed. London, UK: Blackwell Science Ltd; 1997.

  32. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog 2007; 3: e108.

  33. von Hahn T , Rice CM. Hepatitis C virus entry. J Biol Chem 2008; 283: 3689-93.

  34. Fanning L, Kenny E , Sheehan M, Cannon B, Whelton M, O’Connell J, Collins JK, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999; 29: 904-7.

  35. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation and secretion. J Virol 2007; 82: 2120-9.

  36. Lange CM, von Wagner M, Bojunga J, Berg T, Farnik H, Hassler A, Sarrazin C, et al. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-a-2a and ribavirin. Eur J Gastroenterol Hepatol 2010; 22: 1303-7.




2020     |     www.medigraphic.com